Open an account

Filana Therapeutics

FLNA · NASDAQ

$0.6885+$0.0065 (+0.95%)TodayMarket closed ·
Prev close $0.682

About FLNA

Filana Therapeutics, Inc. engages in the development of novel drugs and diagnostics. The company is headquartered in Austin, Texas and currently employs 17 full-time employees. The company went IPO on 2000-07-14. The firm's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. The company has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, is an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.

Employees
17
Headquarters
Austin, Texas
Listed
Jul 14, 2000
Sector
Health Care
Industry
Pharmaceuticals
Website
cassavasciences.com

FLNA key statistics

Market cap
33.26M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.74M
Volume
198.41K
Open price
$0.672
High today
$0.70
Low today
$0.67
52 Week high
$4.69
52 Week low
$0.6701

Filana Therapeutics (FLNA) at a glance

Filana Therapeutics (FLNA) last traded at $0.6885, with a market cap of 33.26M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.67 and $0.70. The current price is 2.8% above the day's low and 1.6% below its high.

Volume so far is 198.41K shares, below the average of 5.74M shares a day.

Over the past year Filana Therapeutics has ranged from $0.6701 to $4.69, and now sits 0% of the way up that range.

Filana Therapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q3 FY25 it reported -$0.22 per share against an estimate of -$0.2754.

The average analyst price target is $0.00, 100.0% below the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 2 analystsAvg $0.00
Low
$0.00
Now
$0.6885
High
$0.00

FLNA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 34.1% on average.

  1. Q3 FY23: reported -$0.61 per share against an estimate of -$0.7905
  2. Q4 FY23: reported -$0.50 per share against an estimate of -$0.5304
  3. Q1 FY24: reported -$0.43 per share against an estimate of -$0.4692
  4. Q2 FY24: reported $0.13 per share against an estimate of -$0.408
  5. Q3 FY24: reported -$0.58 per share against an estimate of -$0.8976
  6. Q4 FY24: reported -$0.57 per share against an estimate of -$0.6681
  7. Q1 FY25: reported -$0.48 per share against an estimate of $0.00
  8. Q3 FY25: reported -$0.22 per share against an estimate of -$0.2754

FLNA news

  • Vandana Singh

    Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward

  • Press releaseGlobe Newswire

    Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

  • Press releasePRNewswire

    Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • Press releaseGlobe Newswire

    Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

  • Press releaseGlobe Newswire

    Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

  • Press releaseGlobe Newswire

    Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII

  • Press releaseGlobe Newswire

    Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data

  • Press releaseGlobe Newswire

    Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Similar companies

Companies in the same industry as Filana Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.